Bradykinin receptor agonist facilitates low-dose cyclosporine-A protection against 6-hydroxydopamine neurotoxicity.

@article{Borlongan2002BradykininRA,
  title={Bradykinin receptor agonist facilitates low-dose cyclosporine-A protection against 6-hydroxydopamine neurotoxicity.},
  author={Cesario V. Borlongan and Dwaine F. Emerich and Barry J. Hoffer and Raymond T. Bartus},
  journal={Brain research},
  year={2002},
  volume={956 2},
  pages={211-20}
}
Cyclosporine-A (CsA) is neuroprotective in animal models of Parkinson's disease (PD), Huntington's disease and stroke. Because CsA does not easily cross the blood-brain barrier (BBB), high doses (i.e. >10 mg/kg in rats) and chronic administration may be necessary to produce beneficial effects. However, immunosuppressant side effects (including nephrotoxicity and hepatotoxicity) are associated with such CsA dosing regimens. The bradykinin B2 receptor agonist, Cereport (labradimil and formerly… CONTINUE READING